EA199800821A1 - Способ лечения аутизма - Google Patents

Способ лечения аутизма

Info

Publication number
EA199800821A1
EA199800821A1 EA199800821A EA199800821A EA199800821A1 EA 199800821 A1 EA199800821 A1 EA 199800821A1 EA 199800821 A EA199800821 A EA 199800821A EA 199800821 A EA199800821 A EA 199800821A EA 199800821 A1 EA199800821 A1 EA 199800821A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
autism
olanzapine
patient
effective amount
Prior art date
Application number
EA199800821A
Other languages
English (en)
Other versions
EA000768B1 (ru
Inventor
Чарльз М. мл. Бисли
Гари Д. Толлефсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA199800821A1 publication Critical patent/EA199800821A1/ru
Publication of EA000768B1 publication Critical patent/EA000768B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Luminescent Compositions (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Transplanting Machines (AREA)

Abstract

Данное изобретение обеспечивает способ лечения аутичного расстройства и/или умственной отсталости, предусматривающий введение эффективного количества оланзапина пациенту, нуждающемуся в таком лечении.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199800821A 1996-03-11 1996-12-04 Способ лечения аутизма EA000768B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1316296P 1996-03-11 1996-03-11
PCT/US1996/019576 WO1997033585A1 (en) 1996-03-11 1996-12-04 Method for treating autism

Publications (2)

Publication Number Publication Date
EA199800821A1 true EA199800821A1 (ru) 1999-02-25
EA000768B1 EA000768B1 (ru) 2000-04-24

Family

ID=21758619

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199800821A EA000768B1 (ru) 1996-03-11 1996-12-04 Способ лечения аутизма

Country Status (19)

Country Link
EP (1) EP0946179B1 (ru)
JP (1) JP2000506860A (ru)
KR (1) KR19990087715A (ru)
CN (1) CN1213970A (ru)
AT (1) ATE249832T1 (ru)
AU (1) AU709181B2 (ru)
BR (1) BR9612552A (ru)
CA (1) CA2248741A1 (ru)
CZ (1) CZ290498A3 (ru)
DE (1) DE69630055T2 (ru)
EA (1) EA000768B1 (ru)
ES (1) ES2206614T3 (ru)
HU (1) HUP9903688A3 (ru)
IL (1) IL126161A0 (ru)
NO (1) NO984197L (ru)
NZ (1) NZ324615A (ru)
PL (1) PL328948A1 (ru)
TR (1) TR199801798T2 (ru)
WO (1) WO1997033585A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69923081T2 (de) 1998-11-23 2005-12-08 Sepracor Inc., Marlborough Desmethylolanzapine enthaltende zusammensetzungen und verfahren
ATE253364T1 (de) * 1998-11-23 2003-11-15 Sepracor Inc Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen
US6174882B1 (en) 1998-11-23 2001-01-16 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
AU2013293167B2 (en) 2012-07-22 2019-04-18 Indiana University Research And Technology Corporation Modulation sAPP, sAPP alpha and BDNF levels in individuals diagnosed with FXS and ASD
PL3058371T3 (pl) 2013-10-14 2021-11-08 Indiana University Research And Technology Corporation Zastosowanie akamprozatu do modulowania aktywacji erk 1-2 w modelach zwierzęcych dla fxs i asd oraz u osób z rozpoznaniem fxs i asd
RU2666598C1 (ru) * 2017-07-14 2018-09-11 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Средство для коррекции расстройств аутистического спектра
KR102285577B1 (ko) 2020-11-11 2021-08-04 김의철 자폐를 가진 유소년의 무약물 치료방법 및 시스템

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
DE69630055T2 (de) 2004-06-03
EP0946179B1 (en) 2003-09-17
JP2000506860A (ja) 2000-06-06
BR9612552A (pt) 1999-07-20
NO984197L (no) 1998-11-03
HUP9903688A3 (en) 2001-12-28
NZ324615A (en) 2000-08-25
EP0946179A1 (en) 1999-10-06
WO1997033585A1 (en) 1997-09-18
IL126161A0 (en) 1999-05-09
PL328948A1 (en) 1999-03-01
TR199801798T2 (xx) 1998-12-21
AU1150197A (en) 1997-10-01
EA000768B1 (ru) 2000-04-24
ES2206614T3 (es) 2004-05-16
HUP9903688A2 (hu) 2000-03-28
NO984197D0 (no) 1998-09-11
KR19990087715A (ko) 1999-12-27
CZ290498A3 (cs) 1999-10-13
CN1213970A (zh) 1999-04-14
DE69630055D1 (de) 2003-10-23
CA2248741A1 (en) 1997-09-18
ATE249832T1 (de) 2003-10-15
EP0946179A4 (en) 2000-04-19
AU709181B2 (en) 1999-08-26

Similar Documents

Publication Publication Date Title
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
DE69722426D1 (de) Isobutylgaba und dessen derivate zur schmerzbehandlung
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
BR9808221A (pt) Método de tratamento de tumor.
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
EA199800821A1 (ru) Способ лечения аутизма
EA199800590A1 (ru) Способ лечения депрессии
EA199800816A1 (ru) Способы лечения и профилактики интерстициального цистита
EA199800864A1 (ru) Способ лечения при боли, вызванной мигренью
EA199800819A1 (ru) Способ лечения биполярного расстройства
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
PT1056458E (pt) Tratamento de dor cronica
EA199800822A1 (ru) Способ лечения избыточной агрессии
ATE501760T1 (de) E5564 zur verwendung in der behandlung von allograft-abstossung oder host-versus-graft- erkrankungen
EA199800818A1 (ru) Способ лечения бессонницы
BR9708037A (pt) Método para o tratamento de abuso de substância
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
EA200300222A1 (ru) Лечение гепатита c с помощью тимозина, интерферона и рибавирина
EA200101043A1 (ru) Способ лечения неврологических или нейропсихиатрических расстройств
UA8280A (ru) Способ лечения псориаза

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU